Literature DB >> 20600356

Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma.

Marlène Guérin1, Johann Guillemot, Erwan Thouënnon, Alice Pierre, Fatima-Zohra El-Yamani, Maité Montero-Hadjadje, Christophe Dubessy, Rabia Magoul, Isabelle Lihrmann, Youssef Anouar, Laurent Yon.   

Abstract

Pheochromocytomas are rare catecholamine-secreting tumors that arise from chromaffin tissue within the adrenal medulla and extra-adrenal sites. Typical clinical manifestations are sustained or paroxysmal hypertension, severe headaches, palpitations and sweating resulting from hormone excess. However, their presentation is highly variable and can mimic many other diseases. The diagnosis of pheochromocytomas depends mainly upon the demonstration of catecholamine excess by 24-h urinary catecholamines and metanephrines or plasma metanephrines. Occurrence of malignant pheochromocytomas can only be asserted by imaging of metastatic lesions, which are associated with a poor survival rate. The characterization of tissue, circulating or genetic markers is therefore crucial for the management of these tumors. Proteins of the granin family and their derived peptides are present in dense-core secretory vesicles and secreted into the bloodstream, making them useful markers for the identification of neuroendocrine cells and neoplasms. In this context, we will focus here on reviewing the distribution and characterization of granins and their processing products in normal and tumoral chromaffin cells, and their clinical usefulness for the diagnosis and prognosis of pheochromocytomas. It appears that, except SgIII, all members of the granin family i.e. CgA, CgB, SgII, SgIV-SgVII and proSAAS, and most of their derived peptides are present in adrenomedullary chromaffin cells and in pheochromocytes. Moreover, besides the routinely used CgA test assays, other assays have been developed to measure concentrations of tissue and/or circulating granins or their derived peptides in order to detect the occurrence of pheochromocytomas. In most cases, elevated levels of these entities were found, in correlation with tumor occurrence, while rarely discriminating between benign and malignant neoplasms. Nevertheless, measurement of the levels of granins and derived peptides improves the diagnostic sensitivity and may therefore provide a complementary tool for the management of pheochromocytomas. However, the existing data need to be substantiated in larger groups of patients, particularly in the case of malignant disease.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600356     DOI: 10.1016/j.regpep.2010.06.003

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  13 in total

Review 1.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

2.  Hypertension in pheochromocytoma: characteristics and treatment.

Authors:  Samuel M Zuber; Vitaly Kantorovich; Karel Pacak
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 3.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

Review 4.  Chromogranin A: a paradoxical player in angiogenesis and vascular biology.

Authors:  Karen B Helle; Angelo Corti
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

5.  Tianeptine interferes with microtubule organization and hormone secretion of pheochromocytoma cells.

Authors:  Vishruti Makani; James Hall; Khola Qamar; Priyanka Jain; Yonggil Jang; Kenneth Hensley; Joshua J Park
Journal:  Mol Cell Endocrinol       Date:  2013-08-07       Impact factor: 4.102

Review 6.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

Review 7.  A Guide to Pheochromocytomas and Paragangliomas.

Authors:  Julie Guilmette; Peter M Sadow
Journal:  Surg Pathol Clin       Date:  2019-09-28

8.  PREDICTIVE VALUE OF CHROMOGRANIN A IN A DIAGNOSIS TOWARDS PHEOCHROMOCYTOMA IN ADRENAL INCIDENTALOMA.

Authors:  S K Zawadzka-Leska; M Radziszewski; K Malec; A Stadnik; U Ambroziak
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

9.  Mass spectrometry identification of granins and other proteins secreted by neuroblastoma cells.

Authors:  Wojciech Rozek; Malgorzata Kwasnik; Janusz Debski; Jan F Zmudzinski
Journal:  Tumour Biol       Date:  2013-03-22

10.  Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma.

Authors:  Johann Guillemot; Marlène Guérin; Erwan Thouënnon; Maité Montéro-Hadjadje; Jérôme Leprince; Hervé Lefebvre; Marc Klein; Mihaela Muresan; Youssef Anouar; Laurent Yon
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.